LA JOLLA, Calif., March 11, 2013 – Sanford-Burnham Medical Research Institute (Sanford-
Burnham) and Mayo Clinic signed a new collaborative agreement to build a pipeline of therapeutic
drugs aimed at a variety of diseases with serious unmet medical needs. Under this agreement,
Mayo Clinic scientists will work with researchers in Sanford-Burnham’s Conrad Prebys Center for
Chemical Genomics (Prebys Center) to conduct early-stage drug discovery, including assay
development, high-throughput screening, and lead identification. Sanford-Burnham, an
independent research institute, is recognized for establishing novel collaborations with clinical
organizations to expedite early-phase drug discovery.
The agreement combines Mayo Clinic’s clinically relevant targets with Sanford-Burnham’s
discovery platform in a translational initiative aimed at advancing a portfolio of projects through
the initial stages of drug discovery. The new agreement builds on a yearlong pilot phase and
expands the number and scope of drug discovery projects derived from Mayo Clinic researchers
that are being conducted at Sanford-Burnham.
“We’re looking forward to further engaging with our Mayo Clinic collaborators as we develop
innovative screens to identify chemical compounds that modulate the activity of clinically relevant
targets,” said Michael Jackson, Ph.D., vice president of drug discovery and development at
Sanford-Burnham. “If successful, these compounds will form the basis of completely novel—‘first
in class’—therapies for devastating diseases such as cancer, Alzheimer’s, and others.”
In Sanford-Burnham’s Prebys Center, Jackson and a team of researchers—many of them recruited
from the pharmaceutical industry—use state-of-the-art, ultra-high throughput screening systems
to sift through the Institute’s compound library, recognized as one of the largest collections in the
nonprofit research community.
“The Mayo Clinic – Sanford-Burnham collaboration provides an avenue for Mayo scientists to
rapidly translate basic science discoveries into screening platforms that will enable new drug
discovery, and a new paradigm in drug development,” said Andrew Badley, M.D., associate dean
of research resources at Mayo Clinic.
Kristiina Vuori, M.D., Ph.D., Sanford-Burnham’s president and interim CEO, agreed, adding that
“this collaborative model provides interactions between researchers with deep expertise in drug
discovery technologies, basic research scientists and clinical scientists that will expedite the drug
discovery process and offer a clinical outlet for testing potential new drugs.”
About Sanford-Burnham Medical Research Institute
Sanford-Burnham Medical Research Institute is dedicated to discovering the fundamental
molecular causes of disease and devising the innovative therapies of tomorrow. Sanford-Burnham
takes a collaborative approach to medical research with major programs in cancer,
neurodegeneration, diabetes, and infectious, inflammatory, and childhood diseases. The Institute is
recognized for its National Cancer Institute-designated Cancer Center and expertise in drug
discovery technologies. Sanford-Burnham is a nonprofit, independent institute that employs 1,200
scientists and staff in San Diego (La Jolla), California, and Orlando (Lake Nona), Florida. For more
information, visit us at sanfordburnham.org.